Progenics Pharma (PGNX) Reports Q4 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update
March 9, 2017 7:32 AM ESTRegistrational Phase 2B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Expected First Quarter 2017Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for Imaging Agent 1404Initiated Phase 2/3 Trial of PyL Imaging AgentIn February 2017, Initiated Phase 1 Trial of PSMA Targeted Therapeutic Candidate 1095Monetized Portion of RELISTOR Royalty Stream through $50 Million TransactionFourth Quarter 2016 RELISTOR (SC and Oral) Net Sales of $16 Million
NEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced financial results and provided a business update for the fourth... More
